Research compound
TB-500
A research name associated with a fragment of thymosin beta-4.
Also discussed as: Thymosin beta-4 fragment · TB500
THE RESEARCH QUESTION
What is being investigated?
The wider thymosin beta-4 literature includes cell movement and tissue repair. The full protein and the fragment marketed as TB-500 are not interchangeable.
EVIDENCE SNAPSHOT
Preclinical / uncertain identity
Results for full-length thymosin beta-4 cannot be treated as proof for a TB-500 vial. The exact identity of the compound matters before any study can be applied.
LIMITS & SAFETY
What should you know?
Human safety evidence for the fragment is inadequate.
FOLLOW THE EVIDENCE
Sources & further reading
- FDA: safety information for bulk substances used in compounding ↗Regulator
- Huberman Lab: Benefits & Risks of Peptide Therapeutics (2024) ↗Commentary
Checked 8 October 2026. Sources may describe different populations, formulations and jurisdictions. This overview is not a systematic review or individual medical advice.
PUT THE EVIDENCE IN CONTEXT
Questions about what you’ve read?
Request an educational conversation with Matthew about the evidence and questions to raise with your medical professional.